Distributed Bio, Inc., headquartered in the United States, is a pioneering biotechnology firm specialising in the development of advanced therapeutic antibodies. Founded in 2012, the company has made significant strides in the biopharmaceutical industry, focusing on innovative solutions for infectious diseases and cancer treatment. With a robust portfolio of proprietary technologies, Distributed Bio offers unique services in antibody discovery and optimisation, leveraging its state-of-the-art platforms to enhance therapeutic efficacy. The company has established a strong market position, recognised for its contributions to the field and collaborations with leading pharmaceutical partners. As a key player in the biotechnology landscape, Distributed Bio continues to push the boundaries of antibody engineering, aiming to deliver transformative therapies that address unmet medical needs.
We don't have data for Distributed Bio, Inc., but we can show you information about their parent organization instead.
View parent company